Aura Biosciences, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Aura Biosciences is holding a special meeting on August 5, 2026, to vote on increasing authorized shares and amending its 2021 Stock Option and Incentive Plan.
NASDAQ
Aura Biosciences, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 11, 2026.
NASDAQ
Aura Biosciences has scheduled its annual stockholder meeting for June 17, 2025, and is providing proxy materials for voting on key proposals, including the election of directors and ratification of the company's auditor.
NASDAQ
Aura Biosciences announces its 2025 Annual Meeting of Stockholders to be held virtually on June 17, 2025, covering director elections and auditor ratification.
NASDAQ
DEFA14A: Aura Biosciences Updates Proxy Statement, Amends Executive and Director Compensation Disclosures
Aura Biosciences amends its proxy statement for the 2024 annual meeting to update disclosures related to executive and director compensation, including changes to named executive officers and corrections to option award calculations.
NASDAQ
Aura Biosciences announces its 2024 Annual Meeting of Stockholders to be held virtually on June 20, 2024, featuring proposals for director elections, officer exculpation amendment, and auditor ratification.
NASDAQ
Aura Biosciences is holding its 2024 Annual Meeting of Stockholders virtually on June 20, 2024, to vote on director elections, officer exculpation, and auditor ratification.